To test Trastzumab binding in HER2+ cancer cells expressing varying levels of CAV1, we first used a panel of GC cell lines (Fig. 1b, Supplementary Fig. 6A, B): the HER2+ GC cell line (WT, NCIN87) and three GC cell lines (AGS, KATOIII, and SNU1) stably expressing HER2 (LV-HER2). Here, ERBB2 is linked to cancer.